News
PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...
PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...
The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.
PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.
PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acqu ...
PHILADELPHIA, PA —PCI Pharma Services announced plans to acquire Ajinomoto Althea, Inc., a San Diego-based contract development and manufacturing organization (CDMO) specializing in sterile fill ...
A pharma business has announced a new three-year charity partnership with Hospice of the Valleys, which provides ...
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes ...
Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...
PCI Pharma Services plans to grow its largest facility by more than 50% with a 545,000-square-foot expansion.
Not letting its expansion efforts idle, contract manufacturer PCI Pharma Services is picking up a 100% stake in Ajinomoto's San Diego-based fill-finish CDMO Ajinomoto Althea. The deal, for which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results